Covaxin turns out to be the father of Covishield in giving problems, 1 out of every 3 people falls ill, flesh, bones and nerves are becoming weak.

Ronit Kawale
Ronit Kawale - Senior Editor
3 Min Read


The threat of the Corona virus epidemic has undoubtedly reduced, but serious side effects of the vaccines administered to prevent it are still coming to light. Recently there were reports of side effects of Covishield, now it is reported that some serious side effects of Covaxin have also been reported.

Covaxin is a COVID-19 vaccine developed by the Indian company Bharat Biotech. times of India According to a news from India, a recently published study claimed that almost one-third i.e. one out of every three people taking Covaxin faced some problems within a year of taking the vaccine.

This research conducted by Banaras Hindu University (BHU) has been published in the journal 'Drug Safety'. Let us know what is the whole matter.

Covaxin side effects

Indian scientists have reported that multiple adverse effects have been seen in a third of more than 900 people who have received Covaxin shots, while upper respiratory tract infections have been found in about 50% of adolescents.

  • Upper respiratory tract infections (such as the common cold)
  • new skin problems
  • Arthritis
  • hypothyroidism
  • eye problem

menstrual problems

The same study also reported that about 5% of women taking Covaxin had menstrual problems.

Skin disorders and headaches

Skin disorders and headaches

The study reported that the general disorders of most people who were vaccinated were cured, but skin disorders persisted in many people even after 8.5 months. About 5% of adults and adolescents reported persistent headaches after 9 months.

Covishield also has many side effects

Covishield also has many side effects

It is noteworthy that this study has come at a time when pharmaceutical company AstraZeneca has admitted that their Covid-19 vaccine technology, which has been used by the Serum Institute of India in India to make the Covishield vaccine, may be available in very small quantities. Is. cases, can cause blood clotting and low platelet count. This condition is also called 'thrombosis with thrombocytopenia syndrome (TTS)'.

How was the study done?

How was the study done?

Covaxin was the second most used COVID-19 vaccine in India after Covishield. The study reported that researchers included 926 people from the Institute of Medical Sciences. All these people had taken Covaxin. Researchers asked these people about long-term “particularly significant adverse events (AESIs)” that occurred a year after vaccination. According to the study, about 48% of adolescents and 43% of adults were suffering from viral upper respiratory tract infections.

To read this story in English Click here

Disclaimer: This article is for general information only. It cannot in any way be a substitute for any medicine or treatment. Always consult your doctor for further details.


, ArticlesDiv.innerHTML += ArticleHTML; , } //Initially fetch and render feeds FetchAndRenderFeeds();

Leave a comment